Dr. Aaron Schimmer - Princess Margaret Cancer Center, University Health Network, Toronto, Ontario
Targeting the mitochondrial protease, ClpP, as a novel therapeutic strategy for AML
Despite recent advances in the new therapies for AML, the outcome for most patients, especially older ones and patients with relapsed disease remains poor, with some subgroups having a two-year survival rate of less than 5%. Although targeted therapies (eg: IDH and FLT3 inhibitors) have recently been approved for patients with AML, most patients don’t respond to these treatments and when responses occur, remissions are brief. While Venetoclax combinations are an exciting breakthrough in AML treatment, most patients relapse within 9 months. Thus, it remains critical to investigate novel ways to target AML using strategies that are rooted in a mechanistic understanding of the disease and the infrastructure AML cells use to survive.